Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Sponsor: Chinese PLA General Hospital
Summary
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.
Official title: Ruxolitinib and Decitabine-Enhanced Conditioning Versus Modified Bu/Cy or BuF Conditioning for the Impact on Relapse of Acute Myeloid Leukemia in First Complete Remission (CR1)After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Prospective Randomized Controlled Trial
Key Details
Gender
All
Age Range
14 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-01-01
Completion Date
2028-12-30
Last Updated
2026-03-20
Healthy Volunteers
No
Interventions
Ruxolitinib, Decitabine
1. Decitabine: 20 mg/m²/day, administered from Day -15 to Day -10. 2. Ruxolitinib: * 10 mg twice daily (bid), Day -15 to Day -5 * 5 mg twice daily (bid), Day -4 to Day -3 * 5 mg once daily (Qd), Day -2
Locations (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, China